Abstract:Background Glioblastoma (GBM) is one of the deadliest cancers with no cure. While conventional MRI has been widely adopted for examining GBM clinically, accurate neuroimaging assessment of tumor histopathology for improved diagnosis, surgical planning, and treatment evaluation, remains an unmet need in the clinical management of GBMs. Methods We employ a novel Diffusion Histology Imaging (DHI) approach, combining diffusion basis spectrum imaging (DBSI) and machine learning, to detect, differentiate, and quantify areas of high cellularity, tumor necrosis, and tumor infiltration in GBM. Results Gd-enhanced T1W or hyper-intense FLAIR failed to reflect the morphological complexity underlying tumor in GBM patients. Contrary to the conventional wisdom that apparent diffusion coefficient (ADC) negatively correlates with increased tumor cellularity, we demonstrate disagreement between ADC and histologically confirmed tumor cellularity in glioblastoma specimens, whereas DBSI-derived restricted isotropic diffusion fraction positively correlated with tumor cellularity in the same specimens. By incorporating DBSI metrics as classifiers for a supervised machine learning algorithm, we accurately predicted high tumor cellularity, tumor necrosis, and tumor infiltration with 87.5%, 89.0% and 93.4% accuracy, respectively. Conclusion Our results suggest that DHI might serve as a favorable alternative to current neuroimaging techniques for guiding biopsy or surgery as well as monitoring therapeutic response in the treatment of glioblastoma. Key Points Clinical MRI lacks specificity and sensitivity in detecting morphological features in GBM. DBSI-derived morphological metrics reflect tumor cellularity, necrosis, and white matter tracts. DHI predicts and classifies key histopathological features of GBM. Importance of the Study Current clinical diagnosis, surgical resection planning, and assessment of treatment response for GBM patients relies heavily on gadolinium enhanced T1-weighted MRI, despite the enhancement is non-specific to tumor growth merely reflecting a disrupted blood-brain barrier. The complex tumor microenvironment and spatial heterogeneity make GBM very difficult to characterize using current clinical imaging modalities. In this study, we developed a novel imaging technique to characterize key histological features of GBM to accurately predict high tumor cellularity, tumor necrosis, and tumor infiltration. Current proof-of-concept approach if validated in a larger cohort of GBM patients could provide a solution resolve issues such as pseudoprogression and radiation necrosis currently plague neuroimaging modalities to assess GBM in living patients.

Tumor Multiregional Mean Apparent Propagator (MAP) Features in Evaluating Gliomas—A Comparative Study With Diffusion Kurtosis Imaging (DKI)

Mean apparent propagator-MRI in evaluation of glioma grade, cellular proliferation, and IDH-1 gene mutation status

Evaluation of Diffuse Glioma Grade and Proliferation Activity by Different Diffusion-Weighted-imaging Models Including Diffusion Kurtosis Imaging (DKI) and Mean Apparent Propagator (MAP) MRI.

Quantitative Analysis of Mean Apparent Propagator-Magnetic Resonance Imaging for Distinguishing Glioblastoma from Solitary Brain Metastasis

Diagnostic performance between MR amide proton transfer (APT) and diffusion kurtosis imaging (DKI) in glioma grading and IDH mutation status prediction at 3 T

Diagnostic performance of gliomas grading and IDH status decoding A comparison between 3D amide proton transfer APT and four diffusion‐weighted MRI models

Predicting IDH mutation status as well as Ki-67 and p53 expression in high-grade gliomas using amide proton transfer-weighted and arterial spin labeling MRI

Diffusion kurtosis imaging in evaluating gliomas: different region of interest selection methods on time efficiency, measurement repeatability, and diagnostic ability

Diffusion heterogeneity and vascular perfusion in tumor and peritumoral areas for prediction of overall survival in patients with high-grade glioma

Brain T1ρ Mapping for Grading and IDH1 Gene Mutation Detection of Gliomas: a Preliminary Study

Diffusion Histology Imaging Detects and Classifies Glioblastoma Pathology Missed by Conventional Magnetic Resonance Imaging

Non-invasive assessment of heterogeneity of gliomas using diffusion and perfusion MRI: correlation with spatially co-registered PET

Evaluation of Key Molecular Markers in Adult Diffuse Gliomas Based on a Novel Combination of Diffusion and Perfusion MRI and MR Spectroscopy

Two Diffusion Kurtosis Imaging Post-Processing Methods for Differentiating Glioma Grades, IDH Mutation Statuses, and Heterogeneity

Distributed parameter model of dynamic contrast-enhanced MRI in the identification of IDH mutation, 1p19q codeletion, and tumor cell proliferation in glioma patients

Differentiation between high-grade gliomas and solitary brain metastases based on multidiffusion MRI model quantitative analysis

Apparent Diffusion Coefficient as Imaging Biomarker for Identifying IDH Mutation, 1p19q Codeletion, and MGMT Promoter Methylation Status in Patients With Glioma

Multiparametric simultaneous hybrid 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging (18F-FDG PET/MRI) incorporating intratumoral and peritumoral regions for grading of glioma

Application of diffusion kurtosis imaging to the study of edema in solid and peritumoral areas of glioma

Glioma grading by microvascular permeability parameters derived from dynamic contrast-enhanced MRI and intratumoral susceptibility signal on susceptibility weighted imaging

Application of Distributed Parameter Model to Assessment of Glioma IDH Mutation Status by Dynamic Contrast-Enhanced Magnetic Resonance Imaging.